Sunitinib and surufatinib, multiple-receptor tyrosine kinase inhibitors that influence VEGFR, are beneficial and approved for advanced pancreatic NETs [11,94] and nonpancreatic NETs [10]. The gene discussed is KDR; the disease is pancreatic neuroendocrine tumor.